Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ) is now available.
Jiangxi Rimag Group Co., Ltd. has announced the launch of the world’s first AI-assisted diagnostic product, developed by Medical Image Insights, a company it has invested in. This product represents a significant advancement in medical imaging AI, transitioning from single-disease models to comprehensive diagnostic capabilities across multiple diseases and organs. The AIR Product is expected to enhance the Group’s imaging services, reduce development costs, and foster industry collaboration, ultimately transforming medical imaging AI into a systematic and collaborative diagnostic tool.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. is a leading medical group in China, specializing in medical imaging. It operates a comprehensive medical imaging platform offering diversified services across the entire medical imaging industry chain, including imaging center services, imaging solution services, and Rimag Cloud services. The Group has partially invested in Medical Image Insights, an AI company focused on developing medical imaging AI tools.
Average Trading Volume: 20,712,311
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.46B
See more insights into 2522 stock on TipRanks’ Stock Analysis page.